Biocon Ltd

Key update

• Biocon entered a global settlement and license with Genentech for Pebrilzo®, a pertuzumab biosimilar.
• Disputes resolved across the U.S., Canada, and other jurisdictions.
• Launch timelines: EU/UK in Q1 CY2027; U.S. in Q3 CY2028; RoW 2026–2028 or earlier.
• Terms of the agreement are confidential.
• Pebrilzo® targets HER2-positive breast cancer and requires regulatory approvals across markets.
• No disclosed financial terms or royalties in the filing.

Biocon Limited: Trading Window closed from October 01, 2026 until 48 hours after declaration of the financial results of the Company for the quarter and half year ending September 30, 2026

MHRA approval for Semglee fill-finish unit in Malaysia

• Biocon Ltd has received MHRA approval for a new Semglee insulin fill-finish line at its Malaysia facility.
• EMA approval for the same fill-finish line was secured in July.

Regulatory milestone

• EMA CHMP issues positive opinion recommending Pebrilzo marketing authorization (Pertuzumab biosimilar) for HER2-positive breast cancer.
• Final European Commission decision expected; if positive, SmPC and EPAR will be published.

Dividend update

• Final dividend of ₹0.50 per equity share for FY2025-26 approved at the 48th AGM (Aug 6, 2026).
• Dividend remitted electronically per mandate to shareholders with registered address but no email.
• Record date for dividend: 3 July 2026; shares on record receive payout.
• If credit not received, contact KFin Technologies Limited, Biocon's Registrar & Transfer Agent.

Meeting Details

• 11-Sep-26; investor roadshow, in-person (1x1/group) in Mumbai with Biocon management.

Meeting Details

• 04-Sep-2026: Nomura Asian Credit Corporate Day 2026; Group interaction; Virtual.

Participants

• Company management meeting with analysts/institutional investors; key participant: Company Secretary & Compliance Officer.

Purpose

• Investor interaction; schedule of meetings with analysts/institutional investors.

Dividend declaration and remittance

• Final dividend of ₹0.50 per equity share approved at the 48th AGM on August 6, 2026.
• Dividend remitted electronically to shareholders as per mandates registered with RTA/DP.
• Record date for entitlement: Friday, July 3, 2026.
• If credit is not received, contact KFin Technologies Limited (RTA).
• Dividend details and remittance confirmation available on Biocon's website.

Transaction details

• Target Company: Biocon Limited.
• Disclosing Party: Mylan Inc (Seller); not part of promoter group.
• Transaction Type: Disposal of equity shares via open-market sale.
• Pre-Transaction Holding: 9,19,67,019 shares (5.64%).
• Encumbrances pre-disposal: Nil.
• Voting rights pre-disposal: Nil.
• Mode and Date: Open market sale on 14 July 2026.
• Post-Transaction Holding: Nil shares.
• Share capital before: INR 8,14,84,70,675; 1,62,96,94,135 equity shares.
• Share capital after: INR 8,14,84,70,675; 1,62,96,94,135 equity shares.
• Total diluted capital after: INR 8,15,82,64,600; 1,63,16,52,920 shares.
• Date of transaction: 14 July 2026.

Regulatory approval in Japan

• Biocon Biologics Ltd. received MHLW marketing approval for pegfilgrastim biosimilar in Japan.
• Global Regulatory Partners Japan serves as the MAH for Biocon's biosimilar.
• Sandoz K.K. will exclusively promote, sell, and distribute the product in Japan.
• There are no disclosed revenue figures or financial impacts yet.
• Product is a Neulasta® biosimilar developed by Biocon Biologics Ltd.